# Recompensation of Exacerbated Liver Insufficiency With Hyperbilirubinemia and/or Encephalopathy and/or Renal Failure

> **NCT00614146** · NA · COMPLETED · sponsor: **Vantive Health LLC** · enrollment: 59 (actual)

## Conditions studied

- Liver Failure

## Interventions

- **DEVICE:** MARS device
- **PROCEDURE:** Standard medical therapy
- **PROCEDURE:** Standard medical therapy

## Key facts

- **NCT ID:** NCT00614146
- **Lead sponsor:** Vantive Health LLC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2008-01
- **Final completion:** 2009-04
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2025-03-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00614146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00614146, "Recompensation of Exacerbated Liver Insufficiency With Hyperbilirubinemia and/or Encephalopathy and/or Renal Failure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00614146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*